KPC Pharmaceuticals, Inc. (600422.SH): Currently, it has formed three major product matrices of plant skin care, oral care, and health preservation.
On July 24th, Gelunhui Investors asked a question to KPC Pharmaceuticals, Inc. (600422.SH) on the Investor Interaction Platform, "What measures does your company plan to take to expand its toothpaste and personal care product sector?" The company replied that KPC Health is based on the company's core characteristic plant resources, such as Sanqi, Qinghao, Tianma, Licorice, etc. and continuously creates products with more efficiency around innovative research and development technology. Currently, it has formed three major product sectors, namely Plant Skin Care, Oral Care, and Health Maintenance. The health sector is currently exploring the development of technology support and competitive barriers from channel marketing to R&D, and building the foundation for the future development of KPC Health.
KPC Pharmaceuticals, Inc. (600422.SH) has no plans to launch health wine.
KPC Pharmaceuticals, Inc. (600422.SH) stated on the investor interactive platform on July 23 that the company currently has no plans to launch health wine.
KPC Pharmaceuticals, Inc. (600422.SH) annual equity distribution in 2023: dividend of 0.20 yuan per share, with stock rights registration on July 30th.
KPC Pharmaceuticals, Inc. (600422.SH) announced the implementation of annual equity distribution for 2023, and the profit distribution this time will be carried out in the form of...
KPC Pharmaceuticals, Inc. focuses on chronic disease management and opens a new chapter in global strategy for elderly health.
Event: The academic seminar on chronic disease management and the Member Representative Conference of the Geriatrics and Geriatric Medicine Society of China's Elderly Chronic Disease Management Branch were successfully held in Peking on June 22, 2024. KPC Pharmaceuticals, Inc. and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. were co-organizers of this conference.
First coverage report on KPC Pharmaceuticals, Inc. (600422): Empowering by China Resources to create a leader in the silver economy.
China Resources Sanjiu Medical & Pharmaceutical will lead the silver hair health industry by acquiring Kunyu Pharmaceutical in 2023, successfully completing the hundred-day and one-year integration: 1) The core management team and board of directors and supervisors were reorganized smoothly; 2) Connected with Sanjiu Commercial Road and empowered channel construction.
KPC Pharmaceuticals, Inc. (600422): Empowered by CR to Become the Leading Company in the Silver Economy.
Investment Highlights: China Resources has taken over and empowered to build the leading company in the silver economy. After the "hundred-day integration" and "one-year integration" period, the two companies have now entered the "three-year integration" phase. The hundred-day integration phase: 1. Continuous major moves, China Resources related executives at the helm.
Express News | KPC Pharmaceuticals, Inc. appoints Gao Tong and Sun Cheng as vice presidents.
Express News | KPC Pharmaceuticals, Inc.: Proposal to acquire 51% equity of Kunming CR Shenghuo Pharmaceutical Co., Ltd. has been approved.
KPC Pharmaceuticals, Inc. (600422): Acquires 51% equity of Huarun Shenghuo, aiding in creating a benchmark enterprise for the Sanqi industry chain.
KPC Pharmaceuticals, Inc. announced that it plans to sign an equity transfer agreement with the controlling shareholder China Resources Sanjiu Medical & Pharmaceutical. It will use self-owned or self-raised funds to acquire China Resources Sanjiu's 51% equity in China Resources Shenghuo for RMB 1.791 billion. After the completion of the acquisition, China Resources Sanjiu will still hold 49% of China Resources Shenghuo.
chinare pharma (03320.HK): KPC Pharmaceuticals, Inc. intends to acquire a 51% stake in Huaren Shenghuo for 1.791 billion yuan.
On June 11th, Gelunhui reported that the board of directors of chinares pharma (03320.HK) has approved a resolution on June 7th, 2024, and approved the equity transfer agreement ("Equity Transfer Agreement") between the non-wholly owned subsidiary of the company, china resources sanjiu medical & pharmaceutical (000999.SZ), and KPC Pharmaceuticals, Inc. (600422.SH). Accordingly, china resources sanjiu medical & pharmaceutical will agree to sell and KPC Pharmaceuticals, Inc. will agree to acquire 51% equity interest in Kunming Huaren Shenghuo Pharmaceutical Co., Ltd. ("Huaren Shenghuo") for a total price of RMB 1.791 billion ("Proposed Internal Restructuring"). As of the date of this announcement, Huaren Shenghuo is owned by china resources san
KPC Pharmaceuticals, Inc. (600422): Acquires CR Sanjiu to address industry competition and become a leader in the silver hair health industry.
Investment Highlights: On June 7, 2024, KPC Pharmaceuticals, Inc. announced that it intends to sign an equity transfer agreement with its affiliate, China Resources Sanjiu Medical & Pharmaceutical, to acquire Kunming China Resources Sheng held by China Resources Sanjiu Medical & Pharmaceutical with its own or self-raised funds of RMB 1.791 billion.
KPC Pharmaceuticals, Inc. (600422): The company plans to acquire 51% equity of Kunming Shenghuo with cash and remains bullish on the first stock of the silver-haired economy.
Event: On June 7, 2024, the company announced that it plans to sign an equity transfer agreement with its affiliate, China Resources Sanjiu, to use its own or self-raised funds to acquire China Resources Shenghuo's 51% equity stake (originally held by China Resources Sanjiu) for 1.791 billion yuan.
KPC Pharmaceuticals, Inc. (600422): Acquisition of CR Sanjiu promotes resource integration, and the production of products in the Sanqi industry is expected to accelerate.
Event: On June 7th, 2024, the company announced that it plans to sign an equity transfer agreement with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to acquire 51% of Kunming China Resources Shenghuo Pharmaceutical Co., Ltd. held by China Resources Sanjiu for 1.791 billion yuan.
KPC Pharmaceuticals, Inc. (600422): Integration with CR Sanctity in sight, collaborative assistance to slow disease management business development.
The company plans to acquire 51% equity of China Resources Shenghuo and accelerate integration. It maintains a "buy" rating. On June 7th, 2024, the company announced that it plans to use its own or self-raised funds to acquire 51% equity of China Resources Shenghuo for 1.791 billion yuan (formerly China Resources Sanke).
China Resources Shenghuo injects kpc pharmaceuticals, inc. into the market for "unified" Xuesetong soft capsules | Speed reading announcement
① Kunming Pharmaceutical Group plans to acquire 51% of China Resources Shenghuo's shares for 1,791 billion yuan. The competition between the company and China Resources Sanjiu in Xuesaitong softgel products will be resolved. ② The assessed value of China Resources Torch's shareholders' equity was RMB 3,512 million. Compared with the book value of net assets of RMB 930 million in its financial statements, the value-added rate reached 277.65%, but the premium rate decreased compared to when China Resources 39 was purchased, and the net profit doubled.
Express News | China Resources Sanjiu Medical & Pharmaceutical plans to transfer 51% equity of Kunming China Resources Holy Fire Pharmaceutical Co., Ltd.
Express News | Kpc Pharmaceuticals, Inc. intends to purchase a 51% equity transfer of China Resources Sanjiu Medical & Pharmaceutical's Huaren Shenghuo for RMB 1.791 billion.
List of A-share restricted stock lifting | June 7
On June 7th, a total of 10 listed companies will have their restricted stocks released, with a total market value of about 8.734 billion yuan. The specific situation of the restricted stocks to be released today is as follows: stock code, restricted stock type, and number of released shares for Kunyao Group (600422), stock-based incentive, 138,200 shares; Sinochem International Corporation (600500), A-share issued for original shareholders and public sale, 450 million shares; Hebei Hengshui Laobaigan Liquor (600550), stock-based incentive, 6.984 million restricted circulating shares; Nanjing King-Friend Biochemical Pharmaceutical (603707), stock-based incentive, 185,700 restricted circulating shares; Tianjin Ruixin Technology (300828), stock-based incentive, 144,000 restricted circulating shares; and Songshan Share (300077), public sale, 6 million shares.
Despite Lower Earnings Than Three Years Ago, KPC PharmaceuticalsInc (SHSE:600422) Investors Are up 155% Since Then
Strong inflow of foreign capital is another trend vane: Middle Eastern tycoons increase their presence in China, and multinational sovereign wealth funds continue to lay out A-shares
① The Abu Dhabi Investment Authority and the Kuwait Investment Authority held a large number of A-share listed companies in the first quarter; ② the Middle East Sovereign Fund also stepped up research on A-shares ③ Other overseas sovereign wealth funds are increasing their layout in the Chinese market.
No Data